Historical or traditional use (may or may not be supported by scientific studies): In the ancient Ayurvedic medical texts of India, the gummy exudate from boswellia is grouped with other gum resins and referred to collectively as guggals. Historically, the guggals were recommended by Ayurvedic physicians for a variety of conditions, including osteoarthritis, rheumatoid arthritis, diarrhea, dysentery, pulmonary disease, and ringworm.

Active constituents: The gum oleoresin consists of essential oils, gum, and terpenoids. The terpenoid portion contains the boswellic acids that have been shown to be the active constituents in boswellia. Today, extracts are typically standardized to contain 37.5“65% boswellic acids.

Studies have shown that boswellic acids have an anti-inflammatory action ”much like the conventional nonsteroidal anti-inflammatory drugs (NSAIDs) used for inflammatory conditions. Boswellia inhibits pro-inflammatory mediators in the body, such as leukotrienes. As opposed to NSAIDs, long-term use of boswellia does not appear to cause irritation or ulceration of the stomach. One small, controlled, double-blind trial has shown that boswellia extract may be helpful for ulcerative colitis.

How much is usually taken?

The standardized extract of the gum oleoresin of boswellia is recommended by many doctors. For rheumatoid arthritis or osteoarthritis, 150 mg of boswellic acids are taken three times per day. As an example, if an extract contains 37.5% boswellic acids, 400 mg of the extract would be taken three times daily. Treatment with boswellia generally lasts eight to twelve weeks. In the one clinical trial to date, people with ulcerative colitis used 550 mg of boswellia extract three times per day.

Are there any side effects or interactions?

Boswellia is generally safe when used as directed. Rare side effects can include diarrhea, skin rash, and nausea. Any inflammatory joint condition should be closely monitored by a physician.

At the time of writing, there were no well-known drug interactions with boswellia.

1.         References:

1.         Safayhi H, Sailer ER, Amnon HPT. 5-lipoxygenase inhibition by acetyl-11-keto-b-boswellic acid. Phytomed 1996;3:71“2.

2.         Safayhi H, Mack T, Saieraj J, et al. Boswellic acids: Novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992;261:1143“6.

3.         Singh GB, Atal CK. Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions 1986;18:407“12.

4.         Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997;2:37“43.

5.         Etzel R. Special extract of Boswellia serrata (H15) in the treatment of rheumatoid arthritis. Phytomed 1996;3:91“4.